Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology

NCT00207298 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT00207298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00207298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology
Lead sponsor
British Columbia Cancer Agency
Phase
Observational
Overall status
Completed
Start date
June 30, 2005
Completion date
August 31, 2015
Enrollment
39,242 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, colorectal neoplasms, lung neoplasms, lymphoma, melanoma